Skip Nav Destination
Issues
1 May 2008
-
Cover Image
Cover Image
A, Hierarchical clustering of network outputs (Euclidean distance, single linkage algorithm). The visualization represents results from the propagation of all our samples (39 GB, 15 AA, and 5 A) through the trained models. Color coding is according to the 3 molecular subtypes which best characterize the samples (blue, ANGIO; red, INTER; orange, LOWER). The only tumor where ANN subtyping does not agree with histopathology is GB154 (highlighted by a black box). Tumors are annotated with genomic information for a total of 7 loci known to be involved in astrocytic tumor genesis and/or progression. Grey boxes indicate homozygous deletion (CDKN2A/CDKN2B/p14ARF), amplification (CDK4, MDM2 and EGFR), or loss of one allele with mutation of the remaining allele (RB1, TP53 and PTEN). Test samples marked 'TEST'. B, Kaplan-Meier survival plot of our 59 astrocytic tumors as defined by our ANN grading results. Blue line, ANGIO; Red line, INTER; Orange line, LOWER. C, Kaplan-Meier survival plot of the 76 Phillips samples as defined by our ANNgrading results using our 59 gene classifiers. D, Kaplan-Meier survival plot of the 65 Freije samples. For details, see Petalidis et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Spotlight on Clinical Response
Review
Research Articles: Therapeutics, Targets, and Development
Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data
Lawrence P. Petalidis; Anastasis Oulas; Magnus Backlund; Matthew T. Wayland; Lu Liu; Karen Plant; Lisa Happerfield; Tom C. Freeman; Panayiota Poirazi; V. Peter Collins
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Christian A. Hassig; Kent T. Symons; Xin Guo; Phan-Manh Nguyen; Tami Annable; Paul L. Wash; Joseph E. Payne; David A. Jenkins; Céline Bonnefous; Carol Trotter; Yan Wang; John V. Anzola; Elena L. Milkova; Timothy Z. Hoffman; Sara J. Dozier; Brandon M. Wiley; Alan Saven; James W. Malecha; Robert L. Davis; Jerry Muhammad; Andrew K. Shiau; Stewart A. Noble; Tadimeti S. Rao; Nicholas D. Smith; Jeffrey H. Hager
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells
Ismael Samudio; Svitlana Kurinna; Peter Ruvolo; Borys Korchin; Hagop Kantarjian; Miloslav Beran; Kenneth Dunner, Jr.; Seiji Kondo; Michael Andreeff; Marina Konopleva
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells
Daniel B. Lipka; Linda S. Hoffmann; Florian Heidel; Boyka Markova; Marie-Christine Blum; Frank Breitenbuecher; Stefan Kasper; Thomas Kindler; Ross L. Levine; Christoph Huber; Thomas Fischer
Cytotoxicity of the matrix metalloproteinase–activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells
Randall W. Alfano; Stephen H. Leppla; Shihui Liu; Thomas H. Bugge; Meenhard Herlyn; Keiran S. Smalley; Jennifer L. Bromberg-White; Nicholas S. Duesbery; Arthur E. Frankel
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis
Karen Liby; Candice C. Black; Darlene B. Royce; Charlotte R. Williams; Renee Risingsong; Mark M. Yore; Xi Liu; Tadashi Honda; Gordon W. Gribble; William W. Lamph; Thomas A. Sporn; Ethan Dmitrovsky; Michael B. Sporn
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.